¾ÅÉ«

Nabriva Therapeutics Implements Trial Interactive Platform to Streamline Development of Phase II Drug Candidate, BC-3781

NEW YORK, September 27, 2011 ¨C ¾ÅÉ« Trial Interactive, a leading provider of product licensing and alliance management, eTMF, and pharmacovigilance solutions, announced today that Nabriva Therapeutics has implemented the Trial Interactive platform. Nabriva is using the platform to collaborate and share information with potential partners for the licensing of the first of a new class of antibiotics, BC-3781, which completed a phase II trial in 2011. BC-3781 is being developed for the treatment of serious multi-drug-resistant skin and skin-structure infections and bacterial pneumonia.

In the fall of 2010, after an extensive evaluation of various other solutions, Nabriva selected Trial Interactive¡¯s platform for its alliance management process. Markus Aigner, Head of IT at Nabriva Therapeutics, commented, ¡°After considering a number of providers, we determined that Trial Interactive had all of the features we were looking for, including real-time reporting on user activity, a user-friendly interface, and the most advanced security controls. Plus, they have a highly knowledgeable life sciences service team that¡¯s on call 24 hours a day.¡±

¡°We are pleased that Nabriva chose Trial Interactive to streamline its licensing process for BC-3781, which showed positive results from the phase II trial. Providing the ability to collaborate with partners in a paperless process is essential to streamlining product development and bringing novel products to market more expeditiously,¡± said Michael Smyth, General Manager of Life Sciences ¾ÅÉ« at ¾ÅÉ«.

Trial Interactive¡¯s solution allows Nabriva to share information with potential partners in a secure, online environment. The platform complies with the FDA¡¯s 21 CFR Part 11 requirements for electronic records. Trial Interactive has an integrated redaction tool that allows Nabriva to remove select confidential information from documents and configure multiple levels of access for different user groups. In addition, the platform¡¯s user interface is available in more than 20 different languages so that potential partners can navigate the site in their preferred languages.

About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva¡¯s current shareholders include: Phase4 Ventures HBM Partners, The Wellcome Trust, Global Life Science Ventures, Novartis Venture Fund and Sandoz.Nabriva Therapeutics is located in Vienna, Austria.

About ¾ÅÉ« Life Science ¾ÅÉ«
¾ÅÉ« Life Science ¾ÅÉ« provides leading web-based platforms, including eTMFs, that enable sponsors, CROs, IRBs, central laboratories and other vendors to maintain and update clinical trial documentation in a secure online collaborative environment. The Trial Interactive platform enables fully searchable solutions including eTMFs and investigator portals. Trial Interactive solutions streamline study timelines and reduce the administrative burdens of global clinical trials. For more information on ¾ÅÉ« Life Science ¾ÅÉ«, please contact us at info@trialinteractive.com or +1 212.400.8848, or visit .
 
About ¾ÅÉ«
With annual revenues of more than $250 million, ¾ÅÉ« is the largest privately held language services provider in the world. From offices in more than 70 cities on five continents, ¾ÅÉ« offers a full range of services in more than 100 languages to multinationals worldwide. With a global network of over 4,000 linguists and subject-area specialists, ¾ÅÉ« is the largest translation company to be fully ISO 9001:2008 and EN 15038:2006 certified. ¾ÅÉ« is headquartered in New York and has regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com